leadingpharm was established in 2005 and was listed on the shanghai stock exchange in 2015 (stock code: 600222). it is a high-tech enterprise providing pharmacy preclinical research, clinical cro and cdmo services to the world. it has been rated as one of the "top ten chinese pharmaceutical r&d companies (ranked no. 1 in 2019/2020)" for many years. the company is headquartered in beijing zhongguancun high-tech park and has established new drug screening and testing platform, drug evaluation platform (animal room, certified by glp, aaalac, cnas), large molecule pilot and large-scale production platform, small molecule cmc research and production platform, cell technology platform and clinical cro platform in lifezhengzhou. the six platforms comply with international standards (fda, ema and nmpagmp) , forming leadingpharm cxo whole industry chain service system. the combination of imitation and creation, driven by dual engines, can provide customers with diversified services throughout the pharmaceutical research and development.
provide one-stop service for global customers
- company news
on october 26, the leadingpharm-hillgene strategic cooperation signing ceremony was successfully held in “the future medical and health leaders forum and the bio innovators academy annual meeting”.
mr. tao xinhua, chairman of leadingpharm, won the honorary title of "top 10 rising star of china’s pharmaceutical industry in 2020 - leader of cxo-whole-industry-chain service system " in the "most influential company press conference of china's pharmaceutical industry in 2020" .
on october 16th in beijing, over 200 new employees of leadingpharm in 2021 gathered in zhongguancun forest park to participate in the second hiking activity in 2021 with the theme of "protecting health and walking with doctors".